NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

皮膚科藥市場調查報告:治療、藥物、處方形態、治療領域、流通管道、各終端用戶 - 全球產業分析、成長預測 (∼2030年)

Dermatology Drugs Market Research Report: By Treatment, Drug, Prescription Mode, Therapy Area, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 992007
出版日期 內容資訊 英文 275 Pages
商品交期: 2-3個工作天內
價格
皮膚科藥市場調查報告:治療、藥物、處方形態、治療領域、流通管道、各終端用戶 - 全球產業分析、成長預測 (∼2030年) Dermatology Drugs Market Research Report: By Treatment, Drug, Prescription Mode, Therapy Area, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030
出版日期: 2020年11月01日內容資訊: 英文 275 Pages
簡介

全球皮膚科藥的市場規模,預計從2017年的215億美元,到2023年達到345億美元,預計在預測期間中8.2%的年複合成長率擴大。

皮膚病的盛行率的上升,是推動皮膚科藥市場成長的最大要素之一。外傷,環境、遺傳要素,及老化,是引起全球很多人皮膚病的最重要要素。

本報告提供全球皮膚科藥市場相關調查分析,市場概要,市場成長的影響要素,各市場區隔、各地區的市場規模和與前一年同期比較成長,及主要企業等相關分析。

目錄

第1章 調查背景

  • 調查目的
  • 市場定義
  • 調查範圍
    • 市場區隔:各治療
    • 市場區隔:各藥物
    • 市場區隔:各處方形態
    • 市場區隔:各治療領域
    • 市場區隔:各流通管道
    • 市場區隔:各終端用戶
    • 市場區隔:各地區
    • 分析期間
    • 市場資料匯報單位
  • 主要相關利益者

第2章 調查手法

  • 2次調查
  • 1次調查
  • 市場規模的估計
  • 資料的三角測量
  • 匯率
  • 調查的前提條件

第3章 摘要整理

第4章 簡介

  • 市場區隔定義
    • 各治療
      • 局部皮質類固醇
      • 類視色素
      • 生技藥品
      • Calcineurin抑制劑
      • 抗組織胺藥
      • 荷爾蒙療法
      • 其他
    • 各藥物
      • Humira
      • Remicade
      • Otezla
      • Stelara
      • Enbrel
      • Cosentyx
      • Neoral
      • Taltz
      • Cubicin
      • Canesten
      • Zyvox
      • Dupixent
      • Protopic
      • Valtrex
      • Eucrisa
      • 其他
    • 各處方形態
      • 處方藥
      • OTC藥
    • 各治療領域
      • 乾癬
      • 異位性皮膚炎
      • 粉刺
      • 酒糟先生皮膚炎
      • 皮膚癌症
      • 傷痕
      • 其他
    • 各流通管道
      • 直接
      • 批發零售
      • 線上
    • 各終端用戶
      • 醫院
      • 診所
      • 美容中心
      • 家庭
      • 其他
  • 市場動態
    • 趨勢
      • 產品的認證
    • 促進因素
      • 老年人口增加
      • 皮膚疾病的發生率的上升
      • 皮膚病的認識的高漲
      • 個人保養品支出增加
      • 皮膚科藥強力的開發平台
      • 對市場預測的成長要素的影響分析
    • 阻礙因素
      • 專利的有效期限和仿製藥的開發
      • 特定等級的治療藥的副作用
      • 對市場預測的阻礙因素的影響分析
    • 市場機會
      • 新興市場上大的可能性
  • COVID-19的影響
  • 波特的五力分析

第5章 全球市場規模與預測

  • 概要
  • 各治療
  • 各藥物
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各地區

第6章 北美的市場規模與預測

  • 概要
  • 各治療
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各國
    • 美國的皮膚科用醫藥品市場
      • 各治療
      • 各流通管道
    • 加拿大的皮膚科用醫藥品市場
      • 各治療
      • 各流通管道

第7章 歐洲的市場規模與預測

  • 概要
  • 各治療
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各國
    • 德國的皮膚科用醫藥品市場
      • 各治療
      • 各流通管道
    • 法國的皮膚科用醫藥品市場
    • 英國的皮膚科用醫藥品市場
    • 義大利皮膚科用醫藥品市場
    • 西班牙的皮膚科用醫藥品市場

第8章 APAC的市場規模與預測

  • 概要
  • 各治療
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各國
    • 日本皮膚科用醫藥品市場
      • 各治療
      • 各流通管道
    • 中國的皮膚科用醫藥品市場
    • 印度的皮膚科用醫藥品市場

第9章 LATAM的市場規模與預測

  • 概要
  • 各治療
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各國

第10章 MEA的市場規模與預測

  • 概要
  • 各治療
  • 各處方形態
  • 各治療領域
  • 各流通管道
  • 各終端用戶
  • 各國

第11章 競爭情形

  • 產品基準
  • 策略性開發
    • 產品的銷售與核准
    • 收購
    • 其他開發

第12章 企業簡介

  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Galderma S.A.
  • GlaxoSmithKline plc
  • Mylan N.V.
  • LEO Pharma A/S
  • Sanofi

第13章 附錄

目錄
Product Code: LS10496

Title:
Dermatology Drugs Market Research Report: By Treatment (Topical Corticosteroids, Retinoids, Biologics, Calcineurin Inhibitors, Antihistamines, Hormone Therapy), Drug (Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, Eucrisa), Prescription Mode (Prescription Drugs, Over-the-Counter Drugs), Therapy Area (Psoriasis, Atopic Dermatitis, Acne, Rosacea, Skin Cancer, Scar), Distribution Channel (Direct, Wholesale/Retail), End User (Hospitals, Clinics, Cosmetic centers, At-home) - Global Industry Analysis and Growth Forecast to 2030.

Due to the rise in the geriatric population, growing prevalence of dermatological diseases, increasing awareness about skin problems, soaring spending capability of the people, and huge pipeline of dermatological drugs, the global dermatology drugs market is expected to advance rapidly during the forecast period (2018-2023). The market is predicted to advance at the CAGR of 8.2% during the forecast period, from its recorded value of $21.5 billion in 2017, to reach $34.5 billion by 2023.

The increasing prevalence of skin diseases is one of the biggest factors boosting the growth of the dermatology drugs market. Trauma, environmental and genetic factors, and aging are some of the most significant factors causing skin diseases in millions of people across the globe. As per the observations of the World Health Organization (WHO), skin diseases are one of the most common forms of health disorders and they affect nearly 900 million people at a time, around the world.

With the increase in age, the proper functioning of the human skin starts to be lost, resulting in the occurrence of various skin diseases, thereby driving the progress of the dermatology drugs market. Moreover, with age, the body also starts experiencing several other problems, such as slow healing of wounds, higher sensitivity to ultraviolet (UV) radiation, greater vulnerability to infections, and reduction in subcutaneous fat. This increases the probability of various skin problems, thereby shooting up the demand for dermatological drugs.

Based on treatment, the dermatology drugs market is divided into multiple categories, namely retinoids, calcineurin inhibitors, hormonal therapy, topical corticosteroids, biologics, antihistamines, and others, wherein the others category includes antifungal, antibacterial, and antiviral agents and enzyme inhibitors. Amongst the different categories, topical corticosteroids had the largest share in the market, in terms of revenue, in 2017. This was primarily due to the rise in the demand for these drugs as a result of the growing prevalence of eczema across the world.

On the basis of geographical analysis, North America recorded the largest share in the dermatology drugs market, of 43.3%, in terms of revenue, in 2017. The key factors which contributed in the high demand for such therapeutics in the region was the rapidly rising awareness amongst the people about the newly developed and launched drugs and the high per capita income. Asia-Pacific (APAC) is predicted to register the fastest growth in the market during the forecast period.

Therefore, it can be concluded that the market, owing to the growing geriatric population across the world and increasing awareness amongst the masses regarding various dermatological drugs, is set to flourish in the coming years.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Treatment
    • 1.3.2 Market Segmentation by Drug
    • 1.3.3 Market Segmentation by Prescription Mode
    • 1.3.4 Market Segmentation by Therapy Area
    • 1.3.5 Market Segmentation by Distribution Channel
    • 1.3.6 Market Segmentation by End User
    • 1.3.7 Market Segmentation by Region
    • 1.3.8 Analysis Period
    • 1.3.9 Market Data Reporting Unit
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Currency Conversion Rates
  • 2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Treatment
      • 4.1.1.1 Topical corticosteroids
      • 4.1.1.2 Retinoids
      • 4.1.1.3 Biologics
      • 4.1.1.4 Calcineurin inhibitors
      • 4.1.1.5 Antihistamines
      • 4.1.1.6 Hormone therapy
      • 4.1.1.7 Others
    • 4.1.2 By Drug
      • 4.1.2.1 Humira
      • 4.1.2.2 Remicade
      • 4.1.2.3 Otezla
      • 4.1.2.4 Stelara
      • 4.1.2.5 Enbrel
      • 4.1.2.6 Cosentyx
      • 4.1.2.7 Neoral
      • 4.1.2.8 Taltz
      • 4.1.2.9 Cubicin
      • 4.1.2.10 Canesten
      • 4.1.2.11 Zyvox
      • 4.1.2.12 Dupixent
      • 4.1.2.13 Protopic
      • 4.1.2.14 Valtrex
      • 4.1.2.15 Eucrisa
      • 4.1.2.16 Others
    • 4.1.3 By Prescription Mode
      • 4.1.3.1 Prescription drugs
      • 4.1.3.2 OTC drugs
    • 4.1.4 By Therapeutic Area
      • 4.1.4.1 Psoriasis
      • 4.1.4.2 Atopic dermatitis
      • 4.1.4.3 Acne
      • 4.1.4.4 Rosacea
      • 4.1.4.5 Skin cancer
      • 4.1.4.6 Scar
      • 4.1.4.7 Others
    • 4.1.5 By Distribution Channel
      • 4.1.5.1 Direct
      • 4.1.5.2 Wholesale/retail
      • 4.1.5.3 Online
    • 4.1.6 By End User
      • 4.1.6.1 Hospitals
      • 4.1.6.2 Clinics
      • 4.1.6.3 Cosmetic centers
      • 4.1.6.4 At-home
      • 4.1.6.5 Others
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Product approvals
    • 4.2.2 Drivers
      • 4.2.2.1 Rising geriatric population
      • 4.2.2.2 Increasing incidence of dermatological diseases
      • 4.2.2.3 Growing awareness on skin diseases
      • 4.2.2.4 Increasing personal care spending
      • 4.2.2.5 Strong pipeline of dermatological drugs
      • 4.2.2.6 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 Patent expiry and generic drug development
      • 4.2.3.2 Side-effects of certain classes of therapeutic drugs
      • 4.2.3.3 Impact analysis of restraints on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Huge potential in emerging markets
  • 4.3 Impact of COVID-19
  • 4.4 Porter's Five Forces Analysis

Chapter 5. Global Market Size and Forecast

  • 5.1 Overview
  • 5.2 By Treatment
  • 5.3 By Drug
  • 5.4 By Prescription Mode
  • 5.5 By Therapy Area
    • 5.5.1 Psoriasis Drugs Market, by Prescription Mode
    • 5.5.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 5.5.3 Acne Drugs Market, by Prescription Mode
    • 5.5.4 Rosacea Drugs Market, by Prescription Mode
    • 5.5.5 Scar Drugs Market, by Prescription Mode
    • 5.5.6 Skin Cancer Drugs Market, by Prescription Mode
  • 5.6 By Distribution Channel
  • 5.7 By End User
  • 5.8 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 Overview
  • 6.2 By Treatment
  • 6.3 By Prescription Mode
  • 6.4 By Therapy Area
    • 6.4.1 Psoriasis Drugs Market, by Prescription Mode
    • 6.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 6.4.3 Acne Drugs Market, by Prescription Mode
    • 6.4.4 Rosacea Drugs Market, by Prescription Mode
    • 6.4.5 Scar Drugs Market, by Prescription Mode
    • 6.4.6 Skin Cancer Drugs Market, by Prescription Mode
  • 6.5 By Distribution Channel
  • 6.6 By End User
  • 6.7 By Country
    • 6.7.1 U.S. Dermatology Drugs Market
      • 6.7.1.1 By treatment
      • 6.7.1.2 By distribution channel
    • 6.7.2 Canada Dermatology Drugs Market
      • 6.7.2.1 By treatment
      • 6.7.2.2 By distribution channel

Chapter 7. Europe Market Size and Forecast

  • 7.1 Overview
  • 7.2 By Treatment
  • 7.3 By Prescription Mode
  • 7.4 By Therapy Area
    • 7.4.1 Psoriasis Drugs Market, by Prescription Mode
    • 7.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 7.4.3 Acne Drugs Market, by Prescription Mode
    • 7.4.4 Rosacea Drugs Market, by Prescription Mode
    • 7.4.5 Scar Drugs Market, by Prescription Mode
    • 7.4.6 Skin Cancer Drugs Market, by Prescription Mode
  • 7.5 By Distribution Channel
  • 7.6 By End User
  • 7.7 By Country
    • 7.7.1 Germany Dermatology Drugs Market
      • 7.7.1.1 By treatment
      • 7.7.1.2 By distribution channel
    • 7.7.2 France Dermatology Drugs Market
      • 7.7.2.1 By treatment
      • 7.7.2.2 By distribution channel
    • 7.7.3 U.K. Dermatology Drugs Market
      • 7.7.3.1 By treatment
      • 7.7.3.2 By distribution channel
    • 7.7.4 Italy Dermatology Drugs Market
      • 7.7.4.1 By treatment
      • 7.7.4.2 By distribution channel
    • 7.7.5 Spain Dermatology Drugs Market
      • 7.7.5.1 By treatment
      • 7.7.5.2 By distribution channel

Chapter 8. APAC Market Size and Forecast

  • 8.1 Overview
  • 8.2 By Treatment
  • 8.3 By Prescription Mode
  • 8.4 By Therapy Area
    • 8.4.1 Psoriasis Drugs Market, by Prescription Mode
    • 8.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 8.4.3 Acne Drugs Market, by Prescription Mode
    • 8.4.4 Rosacea Drugs Market, by Prescription Mode
    • 8.4.5 Scar Drugs Market, by Prescription Mode
    • 8.4.6 Skin Cancer Drugs Market, by Prescription Mode
  • 8.5 By Distribution Channel
  • 8.6 By End User
  • 8.7 By Country
    • 8.7.1 Japan Dermatology Drugs Market
      • 8.7.1.1 By treatment
      • 8.7.1.2 By distribution channel
    • 8.7.2 China Dermatology Drugs Market
      • 8.7.2.1 By treatment
      • 8.7.2.2 By distribution channel
    • 8.7.3 India Dermatology Drugs Market
      • 8.7.3.1 By treatment
      • 8.7.3.2 By distribution channel

Chapter 9. LATAM Market Size and Forecast

  • 9.1 Overview
  • 9.2 By Treatment
  • 9.3 By Prescription Mode
  • 9.4 By Therapy Area
    • 9.4.1 Psoriasis Drugs Market, by Prescription Mode
    • 9.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 9.4.3 Acne Dermatology Drugs Market, by Prescription Mode
    • 9.4.4 Rosacea Drugs Market, by Prescription Mode
    • 9.4.5 Scar Drugs Market, by Prescription Mode
    • 9.4.6 Skin Cancer Drugs Market, by Prescription Mode
  • 9.5 By Distribution Channel
  • 9.6 By End User
  • 9.7 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 Overview
  • 10.2 By Treatment
  • 10.3 By Prescription Mode
  • 10.4 By Therapy Area
    • 10.4.1 Psoriasis Drugs Market, by Prescription Mode
    • 10.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode
    • 10.4.3 Acne Drugs Market, by Prescription Mode
    • 10.4.4 Rosacea Drugs Market, by Prescription Mode
    • 10.4.5 Scar Drugs Market, by Prescription Mode
    • 10.4.6 Skin Cancer Drugs Market, by Prescription Mode
  • 10.5 By Distribution Channel
  • 10.6 By End User
  • 10.7 By Country

Chapter 11. Competitive Landscape

  • 11.1 Product Benchmarking of Key Players
  • 11.2 Strategic Developments
    • 11.2.1 Product Launches and Approvals
    • 11.2.2 Acquisitions
    • 11.2.3 Other Developments

Chapter 12. Company Profiles

  • 12.1 Bausch Health Companies Inc.
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
  • 12.2 Novartis AG
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
    • 12.2.3 Key Financial Summary
  • 12.3 Pfizer Inc.
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 Bristol-Myers Squibb Company
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
    • 12.4.3 Key Financial Summary
  • 12.5 Johnson & Johnson
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
    • 12.5.3 Key Financial Summary
  • 12.6 Merck & Co. Inc.
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
    • 12.6.3 Key Financial Summary
  • 12.7 Amgen Inc.
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
    • 12.7.3 Key Financial Summary
  • 12.8 AbbVie Inc.
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
    • 12.8.3 Key Financial Summary
  • 12.9 Eli Lilly and Company
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Galderma S.A.
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
  • 12.11 GlaxoSmithKline plc
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
    • 12.11.3 Key Financial Summary
  • 12.12 Mylan N.V.
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary
  • 12.13 LEO Pharma A/S
    • 12.13.1 Business Overview
    • 12.13.2 Product and Service Offerings
    • 12.13.3 Key Financial Summary
  • 12.14 Sanofi
    • 12.14.1 Business Overview
    • 12.14.2 Product and Service Offerings
    • 12.14.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

List of Tables

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 PIPELINE DRUGS FOR TREATMENT OF ACNE
  • TABLE 3 PIPELINE DRUGS FOR TREATMENT OF ACTINIC KERATOSIS
  • TABLE 4 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 5 PATENT EXPIRATION OF DERMATOLOGY DRUGS
  • TABLE 6 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 7 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 8 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 9 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2014-2019)
  • TABLE 10 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2020-2030)
  • TABLE 11 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 12 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 13 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 14 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 15 GLOBAL PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 16 GLOBAL PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 17 GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 18 GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 19 GLOBAL ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 20 GLOBAL ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 21 GLOBAL ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 22 GLOBAL ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 23 GLOBAL SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 24 GLOBAL SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 25 GLOBAL SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 26 GLOBAL SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 27 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 28 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 29 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 30 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 31 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2014-2019)
  • TABLE 32 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2020-2030)
  • TABLE 33 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 34 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 35 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 36 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 37 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 38 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 39 NORTH AMERICA PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 40 NORTH AMERICA PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 41 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 42 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 43 NORTH AMERICA ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 44 NORTH AMERICA ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 45 NORTH AMERICA ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 46 NORTH AMERICA ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 47 NORTH AMERICA SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 48 NORTH AMERICA SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 49 NORTH AMERICA SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 50 NORTH AMERICA SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 51 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 52 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 53 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 54 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 55 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2014-2019)
  • TABLE 56 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2020-2030)
  • TABLE 57 U.S. DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 58 U.S. DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 59 U.S. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 60 U.S. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 61 CANADA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 62 CANADA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 63 CANADA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 64 CANADA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 65 EUROPE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 66 EUROPE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 67 EUROPE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 68 EUROPE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 69 EUROPE DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 70 EUROPE DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 71 EUROPE PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 72 EUROPE PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 73 EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 74 EUROPE ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 75 EUROPE ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 76 EUROPE ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 77 EUROPE ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 78 EUROPE ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 79 EUROPE SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 80 EUROPE SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 81 EUROPE SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 82 EUROPE SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 83 EUROPE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 84 EUROPE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 85 EUROPE DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 86 EUROPE DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 87 EUROPE DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2014-2019)
  • TABLE 88 EUROPE DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2020-2030)
  • TABLE 89 GERMANY DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 90 GERMANY DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 91 GERMANY DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 92 GERMANY DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 93 FRANCE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 94 FRANCE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 95 FRANCE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 96 FRANCE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 97 U.K. DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 98 U.K. DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 99 U.K. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 100 U.K. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 101 ITALY DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 102 ITALY DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 103 ITALY DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 104 ITALY DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 105 SPAIN DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 106 SPAIN DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 107 SPAIN DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 108 SPAIN DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 109 APAC DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 110 APAC DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 111 APAC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 112 APAC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 113 APAC DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 114 APAC DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 115 APAC PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 116 APAC PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 117 APAC ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 118 APAC ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 119 APAC ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 120 APAC ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 121 APAC ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 122 APAC ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 123 APAC SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 124 APAC SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 125 APAC SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 126 APAC SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 127 APAC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 128 APAC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 129 APAC DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 130 APAC DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 131 APAC DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2014-2019)
  • TABLE 132 APAC DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2020-2030)
  • TABLE 133 JAPAN DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 134 JAPAN DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 135 JAPAN DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 136 JAPAN DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 137 CHINA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 138 CHINA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 139 CHINA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 140 CHINA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 141 INDIA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 142 INDIA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 143 INDIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 144 INDIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 145 LATAM DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 146 LATAM DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 147 LATAM DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 148 LATAM DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 149 LATAM DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 150 LATAM DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 151 LATAM PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 152 LATAM PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 153 LATAM ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 154 LATAM ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 155 LATAM ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 156 LATAM ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 157 LATAM ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 158 LATAM ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 159 LATAM SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 160 LATAM SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 161 LATAM SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 162 LATAM SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 163 LATAM DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 164 LATAM DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 165 LATAM DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 166 LATAM DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 167 LATAM DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2014-2019)
  • TABLE 168 LATAM DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2020-2030)
  • TABLE 169 MEA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2014-2019)
  • TABLE 170 MEA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2020-2030)
  • TABLE 171 MEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 172 MEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 173 MEA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2014-2019)
  • TABLE 174 MEA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2020-2030)
  • TABLE 175 MEA PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 176 MEA PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 177 MEA ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 178 MEA ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 179 MEA ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 180 MEA ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 181 MEA ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 182 MEA ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 183 MEA SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 184 MEA SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 185 MEA SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2014-2019)
  • TABLE 186 MEA SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2020-2030)
  • TABLE 187 MEA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2019)
  • TABLE 188 MEA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2020-2030)
  • TABLE 189 MEA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2014-2019)
  • TABLE 190 MEA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2020-2030)
  • TABLE 191 MEA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2014-2019)
  • TABLE 192 MEA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2020-2030)
  • TABLE 193 BAUSCH HEALTH COMPANIES INC. - AT A GLANCE
  • TABLE 194 BAUSCH HEALTH COMPANIES INC. - KEY FINANCIAL SUMMARY
  • TABLE 195 NOVARTIS AG - AT A GLANCE
  • TABLE 196 NOVARTIS AG - KEY FINANCIAL SUMMARY
  • TABLE 197 PFIZER INC. - AT A GLANCE
  • TABLE 198 PFIZER INC. - KEY FINANCIAL SUMMARY
  • TABLE 199 BRISTOL-MYERS SQUIBB COMPANY - AT A GLANCE
  • TABLE 200 BRISTOL-MYERS SQUIBB COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 201 JOHNSON & JOHNSON - AT A GLANCE
  • TABLE 202 JOHNSON & JOHNSON - KEY FINANCIAL SUMMARY
  • TABLE 203 MERCK & CO. INC. - AT A GLANCE
  • TABLE 204 MERCK & CO. INC. - KEY FINANCIAL SUMMARY
  • TABLE 205 AMGEN INC. - AT A GLANCE
  • TABLE 206 AMGEN INC. - KEY FINANCIAL SUMMARY
  • TABLE 207 ABBVIE INC. - AT A GLANCE
  • TABLE 208 ABBVIE INC. - KEY FINANCIAL SUMMARY
  • TABLE 209 ELI LILLY AND COMPANY - AT A GLANCE
  • TABLE 210 ELI LILLY AND COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 211 GALDERMA S.A. - AT A GLANCE
  • TABLE 212 GLAXOSMITHKLINE PLC - AT A GLANCE
  • TABLE 213 GLAXOSMITHKLINE PLC - KEY FINANCIAL SUMMARY
  • TABLE 214 MYLAN N.V. - AT A GLANCE
  • TABLE 215 MYLAN N.V. - KEY FINANCIAL SUMMARY
  • TABLE 216 LEO PHARMA A/S - AT A GLANCE
  • TABLE 217 LEO PHARMA A/S - KEY FINANCIAL SUMMARY
  • TABLE 218 SANOFI - AT A GLANCE
  • TABLE 219 SANOFI - KEY FINANCIAL SUMMARY